Gries Financial LLC Has $311,000 Stock Holdings in Centene Co. (NYSE:CNC)

Gries Financial LLC boosted its holdings in shares of Centene Co. (NYSE:CNC) by 74.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,136 shares of the company’s stock after purchasing an additional 2,187 shares during the period. Gries Financial LLC’s holdings in Centene were worth $311,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. raised its position in Centene by 693.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,705,936 shares of the company’s stock worth $103,346,000 after purchasing an additional 1,490,935 shares during the last quarter. Harris Associates L P grew its holdings in Centene by 5.7% during the third quarter. Harris Associates L P now owns 26,314,183 shares of the company’s stock valued at $1,980,932,000 after purchasing an additional 1,420,825 shares during the period. Hotchkis & Wiley Capital Management LLC increased its position in shares of Centene by 15.4% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,203,049 shares of the company’s stock valued at $241,126,000 after buying an additional 428,100 shares in the last quarter. KBC Group NV raised its position in shares of Centene by 27.3% during the fourth quarter. KBC Group NV now owns 1,602,533 shares of the company’s stock worth $97,082,000 after purchasing an additional 343,559 shares during the period. Finally, International Assets Investment Management LLC bought a new position in Centene in the third quarter valued at approximately $236,940,000. 93.63% of the stock is owned by institutional investors.

Centene Trading Up 1.1 %

NYSE CNC opened at $64.64 on Friday. The business’s fifty day moving average is $61.01 and its 200 day moving average is $67.19. Centene Co. has a twelve month low of $55.03 and a twelve month high of $81.42. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64. The company has a market cap of $32.63 billion, a price-to-earnings ratio of 11.22, a price-to-earnings-growth ratio of 0.85 and a beta of 0.45.

Insiders Place Their Bets

In related news, Director H James Dallas acquired 1,693 shares of Centene stock in a transaction dated Monday, December 16th. The stock was bought at an average price of $59.01 per share, with a total value of $99,903.93. Following the transaction, the director now directly owns 1,693 shares in the company, valued at $99,903.93. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas Greco purchased 17,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average cost of $59.75 per share, with a total value of $1,015,750.00. Following the completion of the purchase, the director now owns 19,309 shares of the company’s stock, valued at approximately $1,153,712.75. This represents a 736.25 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 45,010 shares of company stock valued at $2,660,276 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CNC. Wells Fargo & Company reduced their price objective on Centene from $91.00 to $90.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $75.00 price target (down previously from $80.00) on shares of Centene in a research report on Tuesday, December 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $90.00 price objective on shares of Centene in a research report on Wednesday, December 11th. Truist Financial decreased their price objective on Centene from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, Oppenheimer lowered their target price on shares of Centene from $95.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Centene currently has an average rating of “Moderate Buy” and an average target price of $80.92.

Centene Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.